SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 extension data showing slower upper-limb decline on deramiocel has sparked an enthusiastic reaction, with many traders viewing the results as supportive of FDA approval and expecting a share-price rebound. Others caution that the data do not resolve the FDAs concerns over statistical analysis, leaving the November review outcome uncertain.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Attention centers on Microns fiscal Q4 earnings and forward guidance, with traders focused on whether AI-driven HBM and DRAM demand and tight memory supply can sustain pricing and growth. Bulls expect strong results, while others warn that high expectations, memory-cycle concerns, and a new Netlist HBM patent complaint could fuel a sell-the-news reaction.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants sharp rally is being tied by traders to its Oracle partnership and reported work on bank tokenization and interoperability, with many viewing these developments as signs of institutional adoption. Others question whether the partnerships will create meaningful demand for QNT itself, and the conversation also reflects caution about the tokens sharp, volatile swings.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is under pressure amid concerns that Kalshi and Polymarket are taking share from traditional sportsbooks, with uncertainty over how regulators will treat prediction markets adding to sector-wide worries. Bulls counter that DraftKings own DKeX volumes are growing quickly and could benefit whether rivals remain or face restrictions.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp rebound and perceived technical breakout are drawing bullish attention, with traders citing its capped token supply and potential DeFi catalysts such as the Clarity Act. Optimism is tempered by skepticism over whether the move can hold and comparisons with stronger DeFi peers.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FICO shares plunged after the FHFA moved to put VantageScore alongside FICO on a unified Fannie Mae and Freddie Mac mortgage-pricing grid, raising concerns that lenders could switch to a cheaper alternative and erode FICOs pricing power. Traders are divided between seeing a serious threat to its mortgage-scoring moat and viewing the selloff as an overreaction, noting that adoption is not necessarily immediate and FICO remains established with lenders.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is drawing attention after JPMorgan initiated coverage with an Overweight rating, citing promising ABCL635 results, while traders focus on the drugs Phase 2 data and a planned detailed presentation. The community is broadly bullish on the menopause-treatment candidate and the companys pipeline, though some caution that efficacy and safety still need validation in larger trials and debate whether the stocks sharp run-up may pull back.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Attention centers on MoonLakes planned BLA submission for sonelokimab in hidradenitis suppurativa and the related FDA review milestones, with traders also watching for adolescent trial data. Optimists see the filing as a key step for the drugs HS prospects, while skeptics point to the steep selloff, dilution and management concerns, and question whether results in other indications have established a clear competitive edge.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A DEA judges pause in the remaining cannabis rescheduling case, pending review of a GAO report, has delayed the anticipated recommendation on broader Schedule III reclassification and weighed on MSOS. Traders disagree on the impact: some see a serious setback that could prolong uncertainty, while others view it as a procedural delay and a buying opportunity; the pause does not undo the earlier medical-marijuana rescheduling action.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention amid speculation about upcoming ANKTIVA catalysts, particularly a potential FDA decision on expanding its bladder-cancer use, along with trial updates and international commercialization. Bulls expect these developments to support the companys growth and possibly pressure short sellers, while skeptics say the stock needs concrete news and sustained sales progress to break out of its volatile trading pattern.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
